Source: Google NewsPublished on 2021-02-17
Related Articles:
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- AbFero Pharmaceuticals Announces Funding From Cure Parkinson's For Lead Compound SP-420 - WFMZ Allentown February 17, 2021 AbFero Pharmaceuticals Announces Funding From Cure Parkinson's For Lead Compound SP-420 WFMZ Allentown
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
- Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…
- Monthly research review: February 2020 February 29, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Compound That Protects Mitochondria May Be Possible Therapy Candidate for Parkinson’s, Study Suggests November 25, 2019 A small molecule that can protect the function of mitochondria — known as the powerhouses of cells — and prevent cell death can also prevent brain damage in a rodent stroke model, highlighting its potential as a possible therapeutic candidate for neurodegenerative disorders such as Parkinson’s disease, a study has found. The results were published in an article, “A small…
- Compound That Protects Mitochondria May Be Possible Therapy Candidate for Parkinson’s, Study Suggests November 25, 2019 A small molecule that can protect the function of mitochondria — known as the powerhouses of cells — and prevent cell death can also prevent brain damage in a rodent stroke model, highlighting its potential as a possible therapeutic candidate for neurodegenerative disorders such as Parkinson’s disease, a study has found. The results were published in an article, “A small…
- Neuroprotection with Taurine in a Parkinson’s Model System April 5, 2018 “There is no medicine like hope, no incentive so great, and no tonic so powerful as expectation of something tomorrow.” Orison Swett Marden “Hope sees the invisible, feels the intangible, and achieves the impossible.” Helen Keller Introduction: Many of us take levodopa/carbidopa for substantial symptomatic relief; however, this dopamine replacement treatment only relieves symptoms without offering either neuroprotection or neuro-restoration.…
- Monthy research review – December 2019 December 30, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Parkinson’s Disease Research: A Commentary from the Stands and the Playing Field May 11, 2017 “You can have a very bad end with Parkinson’s, but on the other hand, you can be like me, because I’m lucky. I’m not having a bad end.” Margo MacDonald “My age makes me think how valuable life is. How bad is something like Parkinson’s in relation to not having life at all?” Michael J. Fox Introduction: Last month, together…
- Monthly Research Review: Jaunary 2020 January 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020. The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and…
- Emerald Health Pharmaceuticals’ Cannabinoid-Derived Compound Beneficial in Parkinson’s, Mouse Study Finds February 16, 2018 Emerald Health Pharmaceuticals investigational EHP-102 (previously known as VCE-003.2), a patented compound derived from the non-psychotrophic cannabinoid called cannabigerol, has shown anti-inflammatory and neuroprotective properties in a mouse model of Parkinson’s disease. The study “Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor” was published…
- ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis - BioSpace September 9, 2019 ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis BioSpacePimavanserin achieved robust statistical superiority over placebo in time to relapse of dementia-related psychosis at planned interim efficacy analysis ...
- ALS: From ice bucket to centaur November 18, 2020 # # # # Amyotrophic lateral sclerosis (or ALS) is the third most common neurodegenerative condition. It is characterised by the loss of motor neurons, which leads to loss of muscle control. As with Parkinson’s, there is no cure for ALS, and there are only two FDA approved therapies for the condition. Recently, a biotech company – called Amylyx Pharmaceuticals…
- Monthly Research Review – November 2019 November 30, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Taking Action: My Experience as a Parkinson’s Advocate April 14, 2017 Written by Steve Hovey, Davis Phinney Foundation Ambassador This past February, my wife, Nancy, and I had the privilege of representing the Davis Phinney Foundation at the 2017 Parkinson’s Policy Forum in Washington, D.C. hosted by The Michael J. Fox Foundation. The Policy Forum is a 3-day event, culminating with a full day on Capitol Hill to meet with elected officials…
- Monthly Research Review – November 2020 November 30, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Michael J. Fox Foundation Announces New $7M Initiative to Support Parkinson’s Research, Therapy Development March 22, 2018 The Michael J. Fox Foundation (MJFF) announced a new $7 million funding program to support Parkinson’s disease research and accelerate development of new therapeutic targets and biomarkers. Through the program, researchers can request project funding in four major research areas. The organization is now accepting pre-proposals through May 2018, with funding anticipated by November 2018. “We are working diligently toward breakthroughs…
- AMERICAN PARKINSON DISEASE ASSOCIATION CONVENES EXPERTS TO DETERMINE PARKINSON’S DISEASE RESEARCH FUNDING AND TACKLE LACK OF DIVERSITY May 21, 2019 AMERICAN PARKINSON DISEASE ASSOCIATION CONVENES EXPERTS TO DETERMINE PARKINSON’S DISEASE RESEARCH FUNDING AND TACKLE LACK OF DIVERSITY APDA Hosts Top Scientists, Researchers and Neurologists for Two Days to Evaluate Research Projects Vying for Funding and Address Lack of Diversity in PD Research & Care NEW YORK, NY, May 21, 2019 – For two days, the American Parkinson Disease Association (APDA)…
- Nuplazid Eases Depression in Parkinson’s Patients, Phase 2 Trial Shows October 1, 2019 Treatment with Nuplazid (pimavanserin), approved in the U.S. for treating hallucinations and delusions associated with Parkinson’s psychosis, eased depression and sleep problems in patients with Parkinson’s, according to results from a Phase 2 clinical trial. The research, “Open-Label Study of Pimavanserin Patients With Comorbid Parkinson’s Disease and Depression,” was presented at the 2019 International Congress of Parkinson’s Disease and Movement Disorders in Nice,…